DON'T THINK (pt. 2): Paste whatever is on your clipboard right now into the window and hit SUBMIT!

Preliminary analysis suggests CX717, when compared to placebo, increased wakefulness in a dose-related manner and improved performance of those subjects that were impaired

Irvine, CA (May 2, 2005) - Cortex Pharmaceuticals, Inc. (AMEX: COR) announced that preliminary analysis suggests that CX717, when compared to placebo, increased wakefulness in a dose-related manner and improved performance in healthy male subjects that became impaired during 27 hours without sleep. The study was performed in the United Kingdom at the Academic Clinic for Disorders of Sleep and Wakefulness within the Human Psychopharmacology Research Unit at the Medical Research Centre, School of Biomedical and Molecular Sciences, University of Surrey by Dr. Julia Boyle, Acting Director of the Research Unit and Professor Anthony N. Nicholson, Medical Director and Visiting Professor of Aviation Medicine, King’s College London.

According to Dr. Boyle, “There is evidence that it is the low levels of performance in individuals particularly affected by sleep deprivation that are alleviated by CX717, and that this effect is seen with many measures of performance and across the whole dose range studied from 100 mg through 300 mg to 1000 mg.?E

Professor Anthony N. Nicholson, a clinical neuroscientist who specialises in the pharmacology of the sleep-wakefulness continuum, said “We found that all the three doses of CX717 had an alerting effect in subjects deprived of sleep overnight. With the 100 mg dose there was evidence of increased wakefulness overnight, but an alerting effect was not seen during the recovery sleep the following morning. With both the 300 mg and 1000 mg doses the overnight alerting effect extended well into the next day recovery sleep, and the effect was greater with the higher dose. These findings, and the studies on performance, indicate clearly that the alerting effects and the duration of the alerting effects of CX717 are dose related?E

In the study, 16 young healthy men were administered three different doses of CX717 and a placebo control in a randomized, double-blind, four-way crossover design. All subjects were sleep deprived for 27 hours during which time they were tested on measures of memory, attention, vigilance, reaction time, and executive function. Propensity to fall sleep was measured with a modified wakefulness test given at 4 AM on the night of testing. The integrity of recovery sleep was assessed by polysomnography.

Dr. Roger Stoll, Cortex’s Chairman, President & CEO, stated “the results from this study are very encouraging and begin to validate our AMPAKINE pharmacology in humans. This study supports our development approach for CX717. We plan to conduct pilot studies in variety of brain disorders that might benefit from AMPAKINE pharmacology including Alzheimer’s Disease, Attention Deficit Hyperactivity Disorder (ADHD), and sleep disorders.?E

Cortex believes Ampakine compounds could selectively increase cerebral arousal without increasing somatic arousal and may prove useful for improving performance and decreasing the excessive daytime somnolence associated with shift work, narcolepsy and other conditions caused by sleep deprivation. Narcolepsy is an Orphan Drug indication, which could reduce both the cost and time to market for a potential therapeutic agent from Cortex.

About excessive daytime somnolence (EDS)
The National Commission on Sleep Disorders estimates that 40 million Americans are either chronically or intermittently affected with various sleep disorders. In addition to the tremendous personal pain and suffering they inflict, sleep disorders are a tremendous drain on the productivity and safety of our country: falling asleep at the wheel is one of the most costly and devastating problems on American highways; accidents in the workplace due to sleep deprivation are commonplace and damaging to industry; the annual direct cost to society is over $15 billion. Ampakine products may also be useful in the treatment of a variety of sleep disorders associated with EDS including narcolepsy, jet lag and shift work sleep disorder.

Period Ending: 12/31/2004 12/31/2003 12/31/2002 12/31/2001
Liquidity Ratios
Current Ratio n/a n/a n/a n/a
Quick Ratio n/a n/a n/a n/a
Cash Ratio n/a n/a n/a n/a

Profitability Ratios
Gross Margin 92% 92% 90% 82%
Operating Margin 32% 31% 34% 18%
Pre-Tax Margin 28% 27% 29% 8%
Profit Margin 19% 17% 18% 5%
Pre-Tax ROE 23% 24% 27% 10%
After Tax ROE 16% 15% 17% 6%

-- The Ghost of Black Elegance (djperr...), August 30th, 2005.

Je suis la pluie et tu es mes gouttes
Tu es le oui et moi le doute
T'es le bouquet je suis les fleurs
Tu es l'aorte et moi le coeur
Toi t'es l'instant moi le bonheur
Tu es le verre je suis le vin
Toi tu es l'herbe et moi le joint
Tu es le vent j'suis la rafale
Toi la raquette et moi la balle
T'es le jouet et moi l'enfant
T'es le vieillard et moi le temps
Je suis l'iris tu es la pupille
Je suis l'épice toi la papille
Toi l'eau qui vient et moi la bouche
Toi l'aube et moi le ciel qui s'couche
T'es le vicaire et moi l'ivresse
T'es le mensonge moi la paresse
T'es le guépard moi la vitesse
Tu es la main moi la caresse
Je suis l'enfer de ta pécheresse
Tu es le Ciel moi la Terre, hum
Je suis l'oreille de ta musique
Je suis le soleil de tes tropiques
Je suis le tabac de ta pipe
T'es le plaisir je suis la foudre
Tu es la gamme et moi la note
Tu es la flamme moi l'allumette
T'es la chaleur j'suis la paresse
T'es la torpeur et moi la sieste
T'es la fraîcheur et moi l'averse
Tu es les fesses je suis la chaise
Tu es bémol et moi j'suis dièse

T'es le Laurel de mon Hardy
T'es le plaisir de mon soupir
T'es la moustache de mon Trotski
T'es tous les éclats de mon rire
Tu es le chant de ma sirène
Tu es le sang et moi la veine
T'es le jamais de mon toujours
T'es mon amour t'es mon amour

Je suis ton pile
Toi mon face
Toi mon nombril
Et moi ta glace
Tu es l'envie et moi le geste
T'es le citron et moi le zeste
Je suis le thé, tu es la tasse
Toi la putain et moi la passe
Tu es la tombe et moi l'épitaphe
Et toi le texte, moi le paragraphe
Tu es le lapsus et moi la gaffe
Toi l'élégance et moi la grâce
Tu es l'effet et moi la cause
Toi le divan moi la névrose
Toi l'épine moi la rose
Tu es la tristesse moi le poète
Tu es la Belle et moi la Bête
Tu es le corps et moi la tête
Tu es le corps. Hummm !
T'es le sérieux moi l'insouciance
Toi le flic moi la balance
Toi le gibier moi la potence
Toi l'ennui et moi la transe
Toi le très peu moi le beaucoup
Moi le sage et toi le fou
Tu es l'éclair et moi la poudre
Toi la paille et moi la poutre
Tu es le surmoi de mon ça
C'est toi Charybde et moi Scylla
Tu es la mère et moi le doute
Tu es le néant et moi le tout
Tu es le chant de ma sirène
Toi tu es le sang et moi la veine
T'es le jamais de mon toujours
T'es mon amour t'es mon amour

E-Mail This
Printer-Friendly
Reprints
Save Article
By MARIAN BURROS
Published: November 9, 2005
DATAMONITOR, which tracks supermarket sales, has reported that "growth in organic milk is largely driven by continued use of hormones such as rbGH and antibiotics in the conventional dairy industry."

Skip to next paragraph

Bottle of White (November 9, 2005) Monsanto, the chemical company, received approval from the F.D.A. in 1993 to use synthetic bovine growth hormone to increase a cow's milk production.

"We continue to remain confident in the animal and human safety associated with the use of Posilac," Tom Helscher, a Monsanto executive, said yesterday, using the hormone's brand name. But milk from cows treated with rbGH has higher levels of insulin-like growth factor-1, referred to as IGF-1, than that from untreated cows, according to figures Monsanto sent to the F.D.A.

The missing link is whether milk from rbGH-treated cows translates into higher IFG-1 levels in humans than milk from untreated cows.

Research reported in The Journal of Pharmacology and Experimental Therapeutics showed that IGF-1 largely survives digestion.

Studies show that elevated levels of IGF-1 in the body are linked to increased risk of colon, prostate and breast cancer. Susan E. Hankinson of Harvard Medical School, the lead researcher in one such study, said, "Prospective studies see little or no relationship in postmenopausal women, but in premenopausal women, the levels of IGF-1 tended to show positive association."

A report by the Nurses' Health Study at Harvard, involving 1,000 nurses and published in 2002 in Cancer Epidemiology Biomarkers & Prevention, concluded: "The results raise the possibility that milk consumption could influence cancer risk by a mechanism involving IGF-1."

The lead researcher, Dr. Michelle D. Holmes of Harvard Medical School, said the work was based on blood drawn before rbGH was used, adding: "If we were to repeat such a study now, with people drinking milk with rbGH, would be see something different? It might be a bigger problem. It would be interesting and important to find out."

In 2000, the F.D.A. said that the agency "continues to maintain that levels of IGF-1, whether or not from rbGH supplemented cows, are not significant when evaluated against levels of IGF-1 endogenously produced and present in humans."

Next Article in Dining & Wine (10 of 27) >

CLICK ON IT IF YOU KNOW WHAT'S GOOD FOR YOU.

is LEEE even going to read down this far? I WILL NEVER KNOW.

By Patrick Wilson
JOURNAL REPORTER

Give your opinion on this story

>> a d v e r t i s e m e n t > w e b t o o l s

It's a Beautiful Day [Columbia, 1969]
This is on the charts. Get it off. D

hoos be workin graveyard again

keep chelives1986 company

-- BIG HOOS aka the steendriver, Saturday, June 23, 2007 4:32 AM

http://www.emofaces.com/en/smilies/e/evil-smile.gif

http://echosphere.net/star_trek_insp/insp_captkirk.jpg